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Background: During 2009 to 2012, Thailand had encountered 4 distinctive waves of the 2009 pandemic influenza
A(H1N1) (H1N1pdm) outbreaks. Considering the RNA nature of the influenza viral genome, a mutation in
hemagglutinin (HA) gene which led to change in antigenicity of the strains circulating during those epidemic
periods is anticipated. It is also uncertain whether the A/California/07/2009 (H1N1) (CA/07) vaccine strain still
confers protective immunity against those evolved viruses, the causative agents of the later epidemic waves.
Methods: HA gene segments of 10 H1N1pdm isolates obtained during 2009 to 2012 were sequenced and
phylogenetically analysed using ClustalW and MEGA5 programs. A total of 124 convalescent serum samples
collected from patients naturally infected during 3 epidemic waves were employed as tools to investigate for
antigenic change in HA of these 10 circulating H1N1pdm viruses by hemagglutination inhibition (HI) assay.
Results: A phylogenetic analysis showed that the 10 virus isolates were grouped into 4 clusters corresponding to
the time of 4 consecutive outbreaks. An accumulation of amino acid substitutions in HA was observed in viruses
derived from the late epidemic waves. Significantly lower antibody titers were observed when CA/07 was tested
against convalescent sera collected from the 3 waves (p < 0.05) compared to most of Thai isolates; and significantly
lower antibody titers were also obtained when virus isolates, retrieved from the third epidemic wave were tested
against convalescent sera collected during the first and second wave. These results were suggestive of change in
antigenicity of the evolved viruses. Our results also showed some mutation position residing outside the previously
reported antigenic site that may involve in an alteration of the viral antigenicity.
Conclusions: Our study demonstrated that convalescent sera collected from individuals naturally infected with
H1N1pdm virus were successfully used to reveal a statistically significant change in antibody titers against the
currently evolved H1N1pdm viruses as determined by HI assay. Nevertheless, the antibody titers of individual serum
against various viruses were less than 4-folded difference as compared to that against the CA/07 vaccine strain.
Therefore, CA/07 is still a potent vaccine strain for those evolved H1N1pdm viruses.
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In mid-April 2009, the emergence of a novel influenza A
virus was first noticed in Mexico [1]. The virus is a quad-
ruple reassortant, in which the RNA genome is originated
from swine, avian, and human influenza viruses [2,3]. The
virus capable of infecting humans, at the time of its emer-
gence, was antigenically new to the world’s population and
subsequently spread and caused uncontained influenza
outbreaks among humans worldwide. The World Health
Organization (WHO) declared the influenza pandemic
period between June 2009 and August 2010 [4,5]. It
involved over 18,449 laboratory-confirmed deaths re-
ported to WHO [6], which probably under-represents
the total number. On the other hand, an indirect esti-
mation using statistical modeling suggested 201,200
respiratory deaths associated with the H1N1pdm dur-
ing the first year of the virus circulation [7].
Thailand was among the firstly countries in Southeast
Asia that was attacked by the 2009 pandemic influenza.
The first documented case was recorded in May 2009
[8], followed by three subsequent dominant waves of the
epidemics which lasted for 18 months. The Bureau of
Epidemiology, Department of Disease Control, Ministry
of Public Health, reported the first wave between May-
October 2009, followed by the second in November
2009-April 2010, and the third in May-October 2010.
Thailand was heavily attacked by H1N1pdm before the
WHO announcement of the pandemic phase. In addition,
the actual subsidence of the third wave in Thailand was
noted some time after the WHO had announced the end
of the pandemic. In January-June 2010, a monovalent pan-
demic H1N1 vaccine derived from A/California/07/2009
(H1N1) virus (CA/07) was administered to groups of
people at risk in Thailand, including healthcare workers
[8]. Since then, the H1N1pdm virus has replaced the
previous A(H1N1) virus and become the circulating
strain in Thailand and worldwide. At present, CA/07
remains a component of the trivalent seasonal influenza
vaccine together with influenza A(H3N2) and influenza
B strains [9].
Considering the RNA nature of the influenza viral
genome, a high rate of mutation resulting in antigenic
drift is anticipated due to the lack of the proof-reading cap-
acity of viral RNA polymerase. Influenza hemagglutinin
(HA), the surface glycoprotein of a virion, comprises HA1
and HA2 domains. HA1 domain is highly variable; while
HA2 is more conserved. The HA1 domain constitutes
the HA globular head, which consists of Sa, Sb, Ca, and
Cb antigenic sites [10]. HA1 binds sialic acid receptor
on the host cytoplasmic membrane, while HA2 medi-
ates fusion of the viral envelope to the endosomal
membrane. Thus, the HA molecule determines host cell
specificity and induces a protective antibody response
[11,12]. Mutation in the HA gene sometimes results in theHA antigenic change and may result in changing the
strain components of a seasonal trivalent vaccine. The
hemagglutination inhibition (HI) assay is used to measure
HA antibody titer for serodiagnosis or vaccine evaluation.
HI antibody titers equal or greater than 40, either as the
result of natural infection or vaccination, are considered
immune to re-infection or protective against infection
by homologous influenza strains [13]. During the post-
pandemic period, the World Health Organization has
recommended monitoring of the virus for important
genetic and antigenic changes [14]. Knowing the
changes will be useful for prediction of potential future
outbreaks, and maintaining a matching between circu-
lating influenza strains and vaccine strains.
In this study, 10 H1N1pdm strains isolated from Thai
patients during the 4 epidemic waves (2009-2012) were
analysed for genetic and antigenic variation in compari-
son with the CA/07 vaccine strain. A phylogenetic tree
was constructed from their HA gene sequences. These
10 virus isolates were allowed to react with convalescent
sera collected from patients infected during the first 3
epidemic waves; and a possible change in the virus anti-
genicity was analysed based on the levels of the HI anti-
body titers obtained. Although a panel of immune ferret
sera immunized with particular strains is usually employed
for determining the change in virus antigenicity by HI
assay, our study suggested that convalescent sera collected
during different epidemic waves from individuals naturally
infected with H1N1pdm virus might serve as an alterna-
tive tool to reveal an antigenic variation of the evolved
viruses. The 3-dimensional structure of the viral HA, with
mutation, was also predicted by homology modeling.
Results
Analysis of the HA sequences of the Thailand isolates
Detailed information of the 10 H1N1pdm isolates used
in this study is shown in Table 1. Eight strains were iso-
lated during the three epidemic waves which lasted from
May 2009 to August 2010; and two strains were isolated
during post-pandemic period in July 2012 (defined here
as the fourth wave of the Thailand epidemic). Full-length
HA genes of the study viruses were analyzed against
CA/07 (vaccine strain) and other 21 H1N1pdm strains
isolated in Thailand and neighboring countries during
the years 2009-2013, using sequencing data retrieved
from the NCBI influenza database (http://www.ncbi.nlm.
nih.gov/genomes/FLU/). Multiple sequence alignment
showed >97% identity to the HA genes of the 32 viruses
analyzed. The Thailand viruses isolated from each epi-
demic wave were accordingly clustered together, corre-
sponding with the times of epidemics (Figure 1). Although
the viruses from wave 1 and wave 2 were not separated
into distinctive clusters, a clear separation could be
observed with the viruses from wave 3 and wave 4.
Table 1 The 2009 pandemic influenza A(H1N1) viruses used for phylogenetic analysis and HI assay
Virus Month of specimen
collection (yyyy/mm)





A/California/07/2009 - Vac - E4 MD5 CA/07 FJ966974.1
A/Thailand/104/2009 2009/05 1 Mexico imported case MD5 Thai/104 GQ169382
A/Thailand/ICRC-CBI6/2009 2009/06 1 Chonburi, Thailand MD5 CBI6 CY096808
A/Thailand/ICRC-CBI10/2009 2009/06 1 Chonburi, Thailand MD5 CBI10 CY096807
A/Thailand/ICRC-BKK34002/2010 2010/02 2 Bangkok, Thailand MD5 34002 CY096805
A/Thailand/ICRC-BKK34004/2010 2010/02 2 Bangkok, Thailand MD4 34004 CY096806
A/Thailand/ICRC-NMA1/2010 2010/03 2 Nakhon Ratchasima, Thailand MD5 NMA1 CY096809
A/Thailand/ICRC-BKK1/2010 2010/08 3 Bangkok, Thailand MD5 BKK1 CY096803
A/Thailand/ICRC-BKK2/2010 2010/08 3 Bangkok, Thailand MD5 BKK2 CY096804
A/Thailand/ICRC-BKK4/2012 2012/07 4 Bangkok, Thailand MD6 BKK4 KF732010
A/Thailand/ICRC-BKK5/2012 2012/07 4 Bangkok, Thailand MD5 BKK5 KF732011
Vac; vaccine strain.
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HA1 globular head (amino acid positions 42-275 which
spanned the Sa, Sb, Ca, and Cb antigenic sites) and the
HA2 domain of the study viruses were analyzed. The
amino acid changes in those regions were compared
with those of the vaccine strain, CA/07, as the reference
sequence (Table 2). The result showed a higher number
of amino acid substitutions in the viruses collected from
the late epidemic waves than those from the early
epidemic waves. As expected, mutations were more
common in the HA1 domain than the HA2 domain.
Considering the antigenic site, Sa, Sb, Ca, and Cb on the
HA1 globular head, no difference was found in the amino
acid compositions between Thai/104 (the imported virus
from Mexico) and CA/07. However, amino acid substitu-
tion S203T on Ca was noted in all other Thai strains,
while the mutation in Sb was detected in viruses isolated
during the fourth epidemic wave. Surprisingly, no amino
acid change was observed in the Sa and Cb sites. In
addition, the BKK4 strain from the fourth wave con-
tained amino acid substitution K119N, which contrib-
utes to the acquisition of a new N-linked glycosylation
site. Therefore, it is predicted that BKK4 contains 7 gly-
cosylation sites on the HA1 globular head instead of 6
sites as found in the other viruses. Amino acid substitu-
tions that may affect antigenicity and N-linked glycosyl-
ation sites are demonstrated in the homology model of
HA protein in Figure 2.
HI assay of sera from the H1N1pdm patients against
various virus isolates
In this study, convalescent sera collected from laboratory-
confirmed cases of H1N1pdm infection during the three
epidemic waves were tested by HI assay against 11 virus
isolates, including CA/07 virus and 10 Thailand isolates
originating from the four epidemic waves. Using theCA/07 virus as the test antigen, the HI antibody titers
≥40 were found in 81.4% (48 of 59), 71.9% (23 of 32),
and 78.8% (26 of 33) of the convalescent serum samples
collected from the first, second and third epidemic
waves, respectively. Variation in the number of sera with
HI antibody titers ≥40 was found when these panels of
sera were assayed against the Thailand viruses belong-
ing to different epidemic waves (Table 3). The geometric
mean titer (GMT) of HI antibody in sera collected from
the 3 epidemic waves, as assayed against CA/07 and 10
Thailand isolates are shown in Figure 3. The GMT of
sera from the first and second epidemic waves against
CA/07 virus was significantly lower than GMTs against
the Thailand viruses originating from the first and second
epidemic waves (p < 0.05), but not against viruses from
the third wave, which contained a higher number of
amino acid substitution positions. Regarding serum
samples from the third epidemic wave, the GMT against
all viruses were higher than CA/07. Furthermore, BKK4
virus of the fourth wave showed a significantly lower
GMT compared with the BKK5 virus of the same wave,
when reacted with sera from all 3 waves.
Discussion
HA is a viral protein that induces protective antibody
response. With a pressure from neutralizing antibodies
generated upon natural infection or vaccination, changes
in the HA antigenic determinant are driven in order that
the virus can evade the host immune response [15]. It
has been demonstrated that the percentages of amino acid
divergence in HA are highest, when compared with other
genome segments [16]. In this study, HA sequences of 10
Thailand H1N1pdm viruses isolated in 2009-2012 were
analysed genetically against sequencing data from the
NCBI Influenza Virus Resource database. Phylogenetic
analysis showed that the HA genes of our isolates formed
Figure 1 Phylogenetic analysis of HA gene of the 2009 pandemic influenza A(H1N1) viruses. The HA gene sequences of 10 H1N1pdm
Thai isolates, vaccine strain and other viruses retrieved from the NCBI Influenza Virus Resource database were analysed with sequence CY088801
(Thailand-2010/08) as a root of the phylogenetic tree. The GenBank accession numbers, country in which the viruses were detected, and the year
and month of detection, are shown. Bootstrap values of more than 50 are indicated on each branch. Circle, strains isolated in this study; triangle,
vaccine strain.
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i.e., the first, second, third and fourth epidemic waves in
Thailand. The accumulation of nucleotide substitutions
in the late viruses indicated that the H1N1pdm viruses
gradually evolved at the nucleic acid and amino acid
levels during the past 5 years.
We sought to elucidate whether changes in the HA
gene of our viruses affected the ability of HA protein to
react with the anti-HA antibodies naturally raised
in Thai patients. Convalescent sera from H1N1pdm pa-
tients infected during the 3 epidemic waves were assayedagainst 10 H1N1pdm viruses derived from the 4 epi-
demic waves by HI assay, the method with a potential to
detect changes on the HA globular head. It was noticed
that CA/07, the vaccine strain, yielded a statistically
significant lower HI titers than most of the Thailand
viruses originating from different epidemic waves; never-
theless, the antibody titer against CA/07 in individual
serum was less than 4-folded difference as compared to
those Thailand isolates (data not shown). Even though
the cross reactive HI titers of ≥ 40 were found in 33%
of adults of age more than 60 years prior to H1N1pdm
Table 2 Amino acid similarity among the HA proteins of different H1N1pdm isolates, compared with A/California/07/2009
Region Number of amino
acids involved
(position)
Number of amino acid residues identical to A/CA/07/2009 (H1N1) (amino acid substitution position)
Thai/104 CBI6 CBI10 34002 34004 NMA1 BKK1 BKK2 BKK4 BKK5
HA1 globular
head












Sa 13 13 13 13 13 13 13 13 13 13 13
Sb 12 12 12 12 12 12 12 12 12 11 (S185T) 11 (S185T)
Ca 19 19 18 (S203T) 17 (S203T)
(D222G)








Cb 6 6 6 6 6 6 6 6 6 6 6




17 amino acids of the signal peptide starting from M are not included. The first HA position starts from D.
Amino acid residues in Sa, Sb, Ca, and Cb sites of the globular head are defined according to reference [10].




















Figure 2 Surface representation of HA protein. Amino acids associated with antigenic sites (Sb and Ca) and N-glycosylation are highlighted in
orange in (A) side view of HA trimers, (B) side view of HA monomer, (C) top view of HA trimers and (D) top view of HA monomer. Sialic acid is
shown in green. Figures were generated by Discovery Studio Visualizer-Accelrys.
Kosoltanapiwat et al. BMC Research Notes 2014, 7:951 Page 6 of 10
http://www.biomedcentral.com/1756-0500/7/951vaccination [17], 2 (6.1%) of 33 of the acute sera from
our subjects with unknown age possessed this antibody
level (data not shown). Therefore, an issue on cross re-
active antibody present in old aged people that might
affect our laboratory interpretation is less likely in this
study. P83S amino acid substitution in the HA1 globular
head has been observed in all Thailand viruses, but not
CA/07, suggesting that this point mutation may be
associated with an increase in HI titer as investigated
with the Thailand viruses. Nevertheless, P83S substitu-
tion is not located in the previously reported antigenic
sites (Sa, Sb, Ca, and Cb). The sera from all 3 epidemic
waves reacted with the viruses of the first and second
waves at comparable titers, indicating that viruses of the
first and the second waves are not antigenically distinct.
This concurs with a report by the Ministry of Public
Health, Thailand which showed that the attack rate of
H1N1pdm in the second wave was lower than that of
the first wave [8]. This could be due to the protectiveimmunity developed in Thai population after the first
H1N1pdm epidemic wave. Based on amino acid ana-
lysis, the viruses from the third wave which accumu-
lated a high number of amino acid substitutions,
showed relatively poor activity when reacted with sera
from the first and second waves. Observation of the
HA1 globular head has demonstrated amino acid sub-
stitutions I216V and R205K in viruses from the third
wave only, and this might relate to decreased HI titers
when these viruses were used as test antigens. Never-
theless, the substitutions I216V are located outside pre-
viously reported antigenic sites; while R205K is located
on antigenic site Ca. No substitution was found in the
Sa and Cb regions of any virus studied. It is likely that
amino acid residues outside the previously reported
antigenic sites also play a role as additional antigenic
determinants of viruses. Our finding was concordant
with that reported by Deem et al. [18] who employed
an entropy-based method and demonstrated that more
Table 3 Numbers of sera with HI titer ≥40 when tested against different viruses
Virus % with HI titer ≥40
Serum wave 1 (n = 59) Serum wave 2 (n = 32) Serum wave 3 (n = 33)
CA/07 81.4 (48/59) 71.9 (23/32) 78.8 (26/33)
Thailand wave 1
Thai/104 100 (59/59) 100 (32/32) 100 (33/33)
CBI6 98.3 (58/59) 93.8 (30/32) 100 (33/33)
CBI10 91.5 (54/59) 96.9 (31/32) 100 (33/33)
Thailand wave 2
34002 100 (59/59) 90.6 (29/32) 97 (32/33)
34004 96.9 (57/59) 100 (32/32) 100 (33/33)
NMA1 100 (59/59) 93.8 (30/32) 93.3 (31/33)
Thailand wave 3
BKK1 71.2 (42/59) 81.3 (26/32) 100 (33/33)
BKK2 89.8 (53/59) 87.5 (28/32) 97 (32/33)
Thailand wave 4
BKK4 93.2 (55/59) 84.4 (27/32) 100 (33/33)
BKK5 98.3 (58/59) 100 (32/32) 100 (33/33)
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genic site of H1 HA may involve in the HA antigenicity.
D97N, S185T, S203T, D222G, and E374K, observed in
this study, have been reported in viruses from Thailand
and other regions [16,19,20]. S203T present in all viruses
except Thai/104 and S185T present in the viruses of
the fourth wave, were located in the Ca and Sb sites,
respectively. However, their involvement in antigenicity
changes is uncertain. HA protein modeling suggested
that the amino acid position 203 is not located on the
surface of HA trimer. D222G, the mutation found in a
virus isolate from a dead case (CBI10), is previously
shown to be associated with the more virulent pheno-
type in humans and mice [19,21,22]. E374K substitution
on HA2 stalk region has been observed in most of the
H1N1pdm strains isolated after the year 2010 [23]. This
position, in particular, has been found in viruses isolated
from vaccinees who received the monovalent 2009 H1N1
influenza vaccine, and from a number of fatal cases [24].
The E374K is suggestive for an increase in a structural and
acid stability of the HA trimers involving in membrane
fusion, and potentially affects the viral antigenicity and
adaptation [23,25,26]. Among 10 H1N1pdm viruses in
this study, none of our 3 strains in the first epidemic
wave contained this E374K substitution, while it was
detected in all 7 strains isolated in the later epidemic
wave. Four of these 7 strains were isolated from cases of
vaccine failure (BKK1, BKK2, BKK4, and BKK5), but no
case was fatal. The simultaneous occurrences of E374K
with D97N and S203T, and of E374K with S185T among
our Thailand viruses were previously observed among
the strains isolated from the other geographical regions
[19,27]. K119N, a potential glycosylation site on the HA
globular head, was found in BKK4, but not BKK5 virus
derived from the fourth epidemic wave. This substitu-
tion may be responsible for a decrease in GMT when
BKK4 was compared with the BKK5 virus. This K119Nglycosylation site is situated close to the ligand binding
site; hence, it could mask the receptor binding epitope
on the HA surface [10]. It was noted that K119N was
found among the candidate vaccine strains with im-
proved virus yields in eggs [28,29].
Conclusions
Collectively, our results showed a gradual change in HA
proteins of the H1N1pdm viruses isolated in Thailand
during 2009-2012. This variation has resulted in the viral
antigenic changes as a significant difference in HI antibody
titer could be clearly demonstrated when convalescent
sera were cross-checked with the vaccine strain and virus
isolates derived from various epidemic waves. However,
the HI titers found in this study are not more than
4-folded difference, indicating that the current CA/07
vaccine strain should still be effective.
Methods
Subjects and samples
A total of 124 archival samples of convalescent sera
comprised 59 samples collected from male conscripts in
July 2009 during the first epidemic wave, 32 samples
(15 male conscripts and 17 general population of age be-
tween 2-42 years old) collected between December 2009
and March 2010 during the second epidemic wave, and
33 samples collected from male inmates in September
2010 during the third epidemic wave. These sera had
been kept at -20°C until tested. As suggested by occupa-
tion, the ages of male conscripts were approximately
21 years old. Unfortunately, ages of some subjects including
the male inmates were not known. Infection status of the
subjects was confirmed by detection of the viral genome
in respiratory samples by real time reverse transcription-
polymerase chain reaction (real time RT-PCR) using the
protocol established by the U.S. Centers for Disease Control
and Prevention (CDC) [30]. Collection of respiratory and
Figure 3 Antibody titers against the 2009 pandemic influenza A(H1N1) viruses. The H1N1pdm antibody positive convalescent sera
collected during Thailand’s 2009 pandemic influenza outbreaks, wave 1 (A), wave 2 (B), and wave 3 (C), were tested against 11 isolates of 2009
pdmH1N1 viruses by HI assay. Stacked bars show the proportion of samples with different HI titers, while the line denotes the geometric mean
titer (GMT). *represents a statistically lower GMT compared with the GMT of viruses isolated from the same epidemic wave as sera, **represents a
statistical difference between the GMT of BKK4 and BKK5, p < 0.05, tested by Wilcoxon Signed Ranks Test.
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of influenza outbreak by the Bureau of Epidemiology,
Ministry of Public Health. This study which employed
these blood samples was approved by Siriraj Institu-
tional Review Board, Faculty of Medicine Siriraj Hos-
pital, Mahidol University, Thailand.
Viruses
Eleven strains of H1N1pdm, isolated during the years
2009-2012, were employed as test antigens in HI assay.Except for CA/07, which was obtained from the National
Institute for Biological Standards and Control (NIBSC),
UK, all viruses were isolated in Thailand. The HA gene of
these viruses were subjected to nucleotide sequencing,
and the complete HA sequences were submitted to the
NCBI Influenza Virus Resource database (http://www.
ncbi.nlm.nih.gov/genomes/FLU/). Descriptions of the
viruses are shown in Table 1. The viruses were propa-
gated in Madin-Darby Canine Kidney (MDCK) cells,
obtained from the American Type Culture Collection
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medium (Invitrogen, Grand Island, NY) supplemented with
2 μg/ml of L-1-tosylamido-2-phenylethyl chloromethyl
ketone (TPCK)-treated trypsin (Sigma, St. Louis, MO).
The culture supernatant was harvested, centrifuged at
4°C for 15 minutes, aliquoted, and kept frozen as virus
stock at -80°C until used.
Nucleotide sequencing and analysis
Total RNA was extracted from the virus stock by QIAamp®
Viral RNA Mini Kit (QIAGEN Inc., Valencia, CA) using
the procedure described in the manufacturer’s instructions.
The HA gene was amplified by QIAGEN® OneStep
RT-PCR kit (QIAGEN Inc.) using 2 overlapping HA pri-
mer sets: HA1F; 5’ATACGACTAGCAAAAGCAGGGG3’
and HA943R; 5’GAAAKGGGAGRCTGGTGTTTA3’
(product size of 943 bp) and HA736F; 5’AGRATG
RACTATTACTGGAC3’ and HA1778R; 5’GTGTCAGT
AGAAACAAGGGTGTTT3’ (product size 1042 bp).
The protocol for RT-PCR comprised the steps of re-
verse transcription at 50°C for 45 min and PCR activa-
tion at 95°C for 15 min, followed by 5 cycles of
denaturation at 95°C for 30 sec, annealing at 50°C for
30 sec, and extension at 72°C for 1 min, then another
30 cycles of denaturation at 95°C for 30 sec, annealing
at 55°C for 30 sec and extension at 72°C for 1 min, with
the final extension step at 72°C for 10 min. The PCR
products were gel purified and sent to BioDesign Co.,
Ltd., Thailand for nucleotide sequencing. Nucleotide
sequences of the 2 partial HA fragments were assem-
bled using the BioEdit program to yield the full length HA
sequence. A phylogenetic tree was constructed using
the MEGA 5 program, by applying the neighbor-joining
algorithms with Kimura’s two-parameter distance model
and 1,000 bootstrap replicates [16,31]. Prediction of
the potential glycosylation site employed NetNGlyc 1.0
(http://www.cbs.dtu.dk/services/NetNGlyc/). The glyco-
sylation site was defined as Asn-X-Ser/Thr, where X
represents any amino acid, except proline [10].
Hemagglutination inhibition (HI) assay
The HI assay was performed as previously described
[32,33]. The test sera were mixed with receptor-destroying
enzyme (RDE) (Denka Seiken, Tokyo, Japan) at a serum:
RDE ratio of 1: 3, to remove non-specific inhibitor. The
mixture was incubated at 37°C in a water bath for 16-18 h,
followed by heat inactivation at 56°C for 30 min. The
RDE-treated serum was added with 5 volumes of 0.9%
NaCl and 1 volume of 50% erythrocyte followed by
incubation at 4°C for 1 h, to remove non-specific agglu-
tinator. The reaction tube was spun and the treated
serum at a dilution of 1: 10 was obtained. For the HI
assay, the test serum was 2-fold serially diluted from a
starting dilution of 1: 10 to 1: 1280 in a 25 μl volume,and 25 μl of the virus suspension were added to a final
concentration of 4 HA units. After incubation at ambient
temperature for 30 min, 50 μl of 0.5% goose erythrocytes
were added and the mixture was incubated at 4°C for
30 min. HI antibody titers were determined and defined
as the reciprocal of the highest serum dilution that
completely inhibited the hemagglutination reaction.
Each run included positive control serum and back
titration of viral antigen. The experiments were run in
duplicate and the results were presented as geometric
mean titer (GMT). The difference in HI titers of the test
sera as assayed against different virus strains was statis-
tically analyzed by Wilcoxon Signed Ranks Test. The
statistical significance was set at p < 0.05.
Homology modeling
A structural model of the influenza HA molecule was
constructed using SWISS-MODEL, based on homology
modeling using the crystal structure of the HA molecule
of H1N1pdm (PDB ID: 3LZG) as template [34]. The
model obtained was validated by PROCHECK [35].
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